RHA® Redensity, RHA®2, RHA®3 and RHA® Dermal Fillers
FDA premarket approval P170002/S023 · decided 2023-07-05
Approval details
- PMA number
- P170002
- Supplement
- S023
- Supplement type
- 30-Day Notice
- Supplement reason
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Trade name
- RHA® Redensity, RHA®2, RHA®3 and RHA® Dermal Fillers
- Generic name
- Implant, dermal, for aesthetic use
- Applicant
- Teoxane S.A.
- Date received
- 2022-11-01
- Decision date
- 2023-07-05
- Days to decision
- 246 days
- Decision code
- OK30
- Product code
- LMH
- Advisory committee
- General, Plastic Surgery
- Expedited review
- No
- Location
- Geneva
- Statement
- Transfer of approved products from Teoxane S.A. Geneva, Switzerland to Teoxane Meyrin, Switzerland following packaging but before completion of Quality Control batch release.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.